Frequency of Guillain‐Barré Syndrome During the COVID ‐19 Pandemic: A Multicenter Study
Muscle & Nerve · 2025
DOI: 10.1002/mus.28430 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Toshiyuki Hayashi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction/Aims The incidence of Guillain‐Barré syndrome (GBS) during the COVID‐19 pandemic varies according to country. We investigated the changes in the number of patients with GBS and their characteristics who were reported in Tokyo in 2020 at the beginning of the COVID‐19 pandemic, compared to those two years prior.
Methods
Patients with GBS who were admitted between January 2018 and December 2020 to hospitals in Tokyo were retrospectively included. We collected data on preceding infections, clinical symptoms, spinal fluid test results, nerve conduction study results, and anti‐glycolipid antibody levels.
Results
Thirty‐four of 57 hospitals (59.6%) participated in this survey and reported 330 patients with GBS over three years. The number of patients in 2020 ( n = 71) was significantly lower than in 2018 ( n = 124) and 2019 ( n = 135) ( p = 0.0014). The number of patients with antecedent gastroenteritis ( p = 0.03) or upper respiratory tract infections ( p = 0.0003) in 2020 was significantly lower than the averages in 2018 and 2019. Analysis by subtype showed that the number of patients with Miller Fisher syndrome ( p = 0.0009) and Bickerstaff brainstem encephalitis ( p = 0.04) significantly decreased in 2020. The number of patients seropositive for anti‐glycolipid antibodies, especially anti‐GQ1b antibodies, decreased in 2020 ( p = 0.0002).
Discussion
Infection control strategies during the COVID‐19 pandemic resulted in fewer patients with preceding infections in Tokyo, which contributed to a decrease in the overall number of reported patients with GBS. Precautions for infection may reduce the frequency of patients with GBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Nippon Medical School, Tokyo, Japan.
- Department of Neurology, The University of Tokyo, Tokyo, Japan.
- Department of Neurology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
- Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan.
- Department of Neurology, Graduate School of Medicine, Nihon University School of Medicine, Tokyo, Japan.
ORCID-Profile: Toshiyuki Hayashi, Masahiro Sonoo
Zitieren
APA
Hayashi, T., Toda, T., Chiba, A., Hattori, N., Sonoo, M., Nakajima, H., Yokota, T., Iguchi, Y., Murakami, H., Kato, H., Kano, O., Kitagawa, K., Kitagawa, S., Nagayama, H., & Kimura, K. (2025). Frequency of Guillain‐Barré Syndrome During the COVID ‐19 Pandemic: A Multicenter Study. Muscle & Nerve. https://doi.org/10.1002/mus.28430
Vancouver
Hayashi T, Toda T, Chiba A, Hattori N, Sonoo M, Nakajima H, et al. Frequency of Guillain‐Barré Syndrome During the COVID ‐19 Pandemic: A Multicenter Study. Muscle & Nerve. 2025. doi:10.1002/mus.28430
BibTeX
@article{Hayashi2025,
author = {Hayashi, Toshiyuki and Toda, Tatsushi and Chiba, Atsuro and Hattori, Nobutaka and Sonoo, Masahiro and Nakajima, Hideto and Yokota, Takanori and Iguchi, Yasuyuki and Murakami, Hidetomo and Kato, Haruhisa and Kano, Osamu and Kitagawa, Kazuo and Kitagawa, Satoshi and Nagayama, Hiroshi and Kimura, Kazumi},
title = {Frequency of Guillain‐Barré Syndrome During the COVID ‐19 Pandemic: A Multicenter Study},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28430}
}
EUVIMED